Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination

Human Vaccines and Immunotherapeutics

Volumn 14, Issue 2, 2018, Pages 337-344

  Kaaijk, Patricia ^a   Luytjes, Willem ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

epidemiology; flavivirus; surveillance; TBE vaccines; tick borne encephalitis; vaccination strategy; West Nile fever; WNV vaccine development

Indexed keywords

ENCEVIR; TICK BORNE ENCEPHALITIS VACCINE; WEST NILE VACCINE; VIRUS VACCINE;

CASE FATALITY RATE; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DRUG DESIGN; ENCEPHALOMYELITIS; EUROPE; FLAVIVIRUS INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOLOGY; NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); TICK BORNE ENCEPHALITIS; VACCINATION; VIRUS IMMUNITY; VIRUS TRANSMISSION; WEST NILE FEVER; COMMUNICABLE DISEASE; DISEASE NOTIFICATION; HEALTH SURVEY; IMMUNOLOGY; RISK FACTOR;

COMMUNICABLE DISEASES, EMERGING; DISEASE NOTIFICATION; EUROPE; FLAVIVIRUS INFECTIONS; HUMANS; POPULATION SURVEILLANCE; RISK FACTORS; VACCINATION; VIRAL VACCINES;

EID: 85035340780     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1389363     Document Type: Note

References (43)

1. Ishikawa T, Yamanaka A, Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine. 2014;32(12):1326–37. doi:10.1016/j.vaccine.2014.01.040.
2. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine. 2012;30(29):4301–6. doi:10.1016/j.vaccine.2011.09.114.
3. Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine. 2003;21 Suppl 1:S36–40. doi:10.1016/S0264-410X(02)00819-8.
4. Hogrefe WR, Moore R, Lape-Nixon M, Wagner M, Prince HE. Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies. J Clin Microbiol. 2004;42(10):4641–8. doi:10.1128/JCM.42.10.4641-4648.2004.
5. Beck C, Jimenez-Clavero MA, Leblond A, Durand B, Nowotny N, Leparc-Goffart I, Zientara S, Jourdain E, Lecollinet S. Flaviviruses in Europe: Complex circulation patterns and their consequences for the diagnosis and control of West Nile disease. Int J Environ Res Public Health. 2013;10(11):6049–83. doi:10.3390/ijerph10116049.
6. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe. 2008;4(3):229–38. doi:10.1016/j.chom.2008.08.004.
7. Mansfield KL, Horton DL, Johnson N, Li L, Barrett AD, Smith DJ, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92(Pt 12):2821–9. doi:10.1099/vir.0.031641-0.
8. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328(5979):745–8. doi:10.1126/science.1185181.
9. Amicizia D, Domnich A, Panatto D, Lai PL, Cristina ML, Avio U, et al. Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. Hum Vaccin Immunother. 2013;9(5):1163–71. doi:10.4161/hv.23802.
10. Kollaritsch H, Paulke-Korinek M, Holzmann H, Hombach J, Bjorvatn B, Barrett A. Vaccines and vaccination against tick-borne encephalitis. Expert Rev Vaccines. 2012;11(9):1103–19. doi:10.1586/erv.12.86.
11. http://ecdc.europa.eu/en/healthtopics/emerging_and_vector-borne_diseases/tick_borne_diseases/tick_borne_encephalitis/Pages/Annual-epidemiological-report-2016.aspx. Annual epidemiological report 2015; Tick-borne encephalitis (reporting on 2014 data) European Centre for Disease Prevention and Control (ECDC, Stockholm). 2016.
12. Zambito Marsala S, Pistacchi M, Gioulis M, Mel R, Marchini C, Francavilla E. Neurological complications of tick borne encephalitis: the experience of 89 patients studied and literature review. Neurol Sci. 2014;35(1):15–21. doi:10.1007/s10072-013-1565-8.
13. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994–98: A prospective study of 656 patients. Brain. 1999;122 (Pt 11):2067–78. doi:10.1093/brain/122.11.2067.
14. Ruzek D, Dobler G, Donoso Mantke O. Tick-borne encephalitis: Pathogenesis and clinical implications. Travel Med Infect Dis. 2010;8(4):223–32. doi:10.1016/j.tmaid.2010.06.004.
15. Charrel RN, Attoui H, Butenko AM, Clegg JC, Deubel V, Frolova TV, Gould EA, Gritsun TS, Heinz FX, Labuda M, et al. Tick-borne virus diseases of human interest in Europe. Clin Microbiol Infect. 2004;10(12):1040–55. doi:10.1111/j.1469-0691.2004.01022.x.
16. Heinz FX, Stiasny K, Holzmann H, Grgic-Vitek M, Kriz B, Essl A, et al. Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis. 2013;19(1):69–76. doi:10.3201/eid1901.120458.
17. Amanna IJ, Slifka MK. Current trends in West Nile virus vaccine development. Expert Rev Vaccines. 2014;13(5):589–608. doi:10.1586/14760584.2014.906309.
18. Rizzoli A, Jimenez-Clavero MA, Barzon L, Cordioli P, Figuerola J, Koraka P, Martina B, Moreno A, Nowotny N, Pardigon N, et al. The challenge of West Nile virus in Europe: knowledge gaps and research priorities. Euro Surveill. 2015;20(20):pii=21135. doi:10.2807/1560-7917.ES2015.20.20.21135.
19. Linke S, Ellerbrok H, Niedrig M, Nitsche A, Pauli G. Detection of West Nile virus lineages 1 and 2 by real-time PCR. Journal of virological methods. 2007;146(1–2):355–8. doi:10.1016/j.jviromet.2007.05.021.
20. http://www.who.int/mediacentre/factsheets/fs354/en/. West Nile virus. WHO Fact sheet No 354. July 2011.
21. Fechter-Leggett E, Nelms BM, Barker CM, Reisen WK. West Nile virus cluster analysis and vertical transmission in Culex pipiens complex mosquitoes in Sacramento and Yolo Counties, California, 2011. J Vector Ecol. 2012;37(2):442–9. doi:10.1111/j.1948-7134.2012.00248.x.
22. Murray KO, Walker C, Gould E. The virology, epidemiology, and clinical impact of West Nile virus: A decade of advancements in research since its introduction into the Western Hemisphere. Epidemiol Infect. 2011;139(6):807–17. doi:10.1017/S0950268811000185.
23. Petersen LR, Carson PJ, Biggerstaff BJ, Custer B, Borchardt SM, Busch MP. Estimated cumulative incidence of West Nile virus infection in US adults, 1999–2010. Epidemiol Infect. 2013;141(3):591–5. doi:10.1017/S0950268812001070.
24. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, Cooper MJ, Katz N, Liljebjelke KA, Biggerstaff BJ, Fine AD, et al. Epidemic West Nile encephalitis, New York, 1999: Results of a household-based seroepidemiological survey. Lancet. 2001;358(9278):261–4. doi:10.1016/S0140-6736(01)05480-0.
25. Gyure KA. West Nile virus infections. J Neuropathol Exp Neurol. 2009;68(10):1053–60. doi:10.1097/NEN.0b013e3181b88114.
26. https://www.cdc.gov/westnile/resources/pdfs/data/2-west-nile-virus-disease-cases-reported-to-cdc-by-state_1999-2015_07072016.pdf. West Nile virus disease cases reported to CDC by state of residence, 1999–2015. Centers for Disease Control and Prevention (CDC). 2015.
27. http://ecdc.europa.eu/en/healthtopics/west_nile_fever/Pages/Annual-epidemiological-report-2016.aspx. Annual epidemiological report; West Nile fever (reporting on 2014 data) European Centre for Disease Prevention and Control (ECDC, Stockholm). 2016.
28. https://ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc. Disease data from ECDC Surveillance Atlas–West Nile fever. ECDC (Stockholm), West Nile fever maps. 2017.
29. Prince HE, Tobler LH, Lape-Nixon M, Foster GA, Stramer SL, Busch MP. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol. 2005;43(9):4316–20. doi:10.1128/JCM.43.9.4316-4320.2005.
30. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J Virol. 2004;78(15):8312–21. doi:10.1128/JVI.78.15.8312-8321.2004.
31. Wang Y, Lobigs M, Lee E, Mullbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol. 2003;77(24):13323–34. doi:10.1128/JVI.77.24.13323-13334.2003.
32. De Filette M, Ulbert S, Diamond M, Sanders NN. Recent progress in West Nile virus diagnosis and vaccination. Vet Res. 2012;43:16. doi:10.1186/1297-9716-43-16.
33. Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis. 2011;203(1):75–84. doi:10.1093/infdis/jiq003.
34. Dayan GH, Bevilacqua J, Coleman D, Buldo A, Risi G. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults >/ = 50 years of age. Vaccine. 2012;30(47):6656–64. doi:10.1016/j.vaccine.2012.08.063.
35. Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011;203(10):1396–404. doi:10.1093/infdis/jir054.
36. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis. 2007;196(12):1732–40. doi:10.1086/523650.
37. Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, Wanionek K, Speicher J, Whitehead SS, Pletnev AG. The live attenuated chimeric vaccine rWN/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers. Vaccine. 2013;31(48):5772–7. doi:10.1016/j.vaccine.2013.07.064.
38. Pierce KK, Whitehead SS, Kirkpatrick BD, Grier PL, Jarvis A, Kenney H, Carmolli MP, Reynolds C, Tibery CM, Lovchik J, et al. A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Delta30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. J Infect Dis. 2017;215(1):52–5. doi:10.1093/infdis/jiw501.
39. Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, et al. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations. PLoS One. 2016;11(2):e0149610. doi:10.1371/journal.pone.0149610.
40. Brandler S, Tangy F. Vaccines in development against West Nile virus. Viruses. 2013;5(10):2384–409. doi:10.3390/v5102384.
41. Ashraf U, Ye J, Ruan X, Wan S, Zhu B, Cao S. Usutu virus: an emerging flavivirus in Europe. Viruses. 2015;7(1):219–38. doi:10.3390/v7010219.
42. Allering L, Jost H, Emmerich P, Gunther S, Lattwein E, Schmidt M, Seifried E, Sambri V, Hourfar K, Schmidt-Chanasit J, et al. Detection of Usutu virus infection in a healthy blood donor from south-west Germany, 2012. Euro Surveill. 2012;17(50):pii=20341.
43. Smit R, Postma MJ. Vaccines for tick-borne diseases and cost-effectiveness of vaccination: A public health challenge to reduce the diseases' burden. Expert Rev Vaccines. 2016;15(1):5–7. doi:10.1586/14760584.2016.1111142.